Home > Oncology > ESMO 2020 > Genitourinary Cancers > Second- and third-line treatment options in mUC

Second- and third-line treatment options in mUC

Conference
ESMO 2020
Avelumab as maintenance therapy after first-line treatment prolonged overall survival (OS) in urothelial cancer (UC). However, predictive biomarkers are not yet found. In addition, sacituzumab govitecan showed promising activity in third (or later) lines. Platinum-based chemotherapy is an active first-line regimen for advanced and mUC. However, progression-free survival (PFS) and OS are generally short because of chemotherapy resistance. The phase 3 JAVELIN Bladder 100 trial (n=700) evaluated avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced UC [1]. The study met its primary objective, demonstrating significantly prolonged OS with maintenance avelumab plus best supportive care versus best supportive care alone in all randomised patients and patients with PD-L1 positive tumours. In addition, an exploratory analysis of predictive biomarkers was performed to identi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on